← Eichor
Study identifier: NCT06646913 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

TENS in Scleroderma

Condition: Scleroderma · Gastroparesis · Systemic Sclerosis (SSc)  ·  Sponsor: University of Michigan

PhasePhase 1
Planned participants16
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is: To evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating in individuals diagnosed with Scleroderma. Participants will be provided with the TEA devices that will be applied to the skin for a total of 45 minutes twice daily after meals. Participants will be asked to fill out both daily diaries and biweekly questionnaires to assess for improvement in the gastroparesis symptoms. Participants will also be asked to complete the daily diaries in addition weekly questionnaires during a 4 week post-treatment follow-up period.

This description comes directly from the study's public registry record.

Talk to the study team

Dinesh Khanna, MD, MSc  ·  734-936-5615  ·  khannad@med.umich.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of MichiganAnn Arbor, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06646913